線維芽細胞増殖因子受容体4(FGFR4)拮抗薬市場

当レポートでは、線維芽細胞増殖因子受容体4(FGFR4)拮抗薬市場について調査し、市場の概要とともに、薬剤開発段階別の概要、主な製品とアンメットニーズ、および市場に参入する主要企業などを提供しています。

目次

イントロダクション

エグゼクティブサマリー

線維芽細胞成長因子受容体4（FGFR4）拮抗薬：概要

• 線維芽細胞成長因子受容体4（FGFR4）拮抗薬とは何か
• 線維芽細胞成長因子受容体4（FGFR4）拮抗薬の種類
• 原因
• 疫学と危険因子
• 病気の管理

パイプライン治療

• 比較解析

治療的評価

• 製品タイプ別評価
• 病期および製品タイプ別評価
• 投与経路別評価
• 投与の段階と経路別評価
• 分子タイプ別評価
• 病期および分子タイプ別評価

線維芽細胞成長因子受容体4（FGFR4）拮抗薬-DelveInsightの分析的展望

後期製品（第III相）

• 比較解析

インフィグラチニブ：Helsinn

• 製品説明
• 研究開発
• 製品開発活動

ミッドステージ製品（第II相）

• 比較解析

ペミガチニブ：Incyte Corporation

• 製品説明
• 研究開発
• 製品開発活動

初期段階の製品（第I相）

H3B 6527：H3 Biomedicine

• 製品説明
• 研究開発
• 製品開発活動

前臨床段階の製品

• 比較解析

ASP5878：Astellas Pharma

• 製品説明
• 研究開発
• 製品開発活動

非アクティブな製品

• 比較解析

線維芽細胞成長因子受容体4（FGFR4）拮抗薬主要企業

線維芽細胞成長因子受容体4（FGFR4）拮抗薬の主要製品

線維芽細胞成長因子受容体4（FGFR4）拮抗薬-アンメットニーズ

線維芽細胞成長因子受容体4（FGFR4）拮抗薬-市場促進要因と抑制要因

線維芽細胞成長因子受容体4（FGFR4）拮抗薬-将来の展望と結論

線維芽細胞成長因子受容体4（FGFR4）拮抗薬-アナリストの見解

線維芽細胞成長因子受容体4（FGFR4）拮抗薬-主要企業

付録

List of Tables

• Table 1 Total Products for Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist
• Table 2 Late Stage Products
• Table 3 Mid Stage Products
• Table 4 Early Stage Products
• Table 5 Pre-clinical & Discovery Stage Products
• Table 6 Assessment by Product Type
• Table 7 Assessment by Stage and Product Type
• Table 8 Assessment by Route of Administration
• Table 9 Assessment by Stage and Route of Administration
• Table 10 Assessment by Molecule Type
• Table 11 Assessment by Stage and Molecule Type
• Table 12 Inactive Products

List of Figures

• Figure 1 Total Products for Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist
• Figure 2 Late Stage Products
• Figure 3 Mid Stage Products
• Figure 4 Early Stage Products
• Figure 5 Preclinical and Discovery Stage Products
• Figure 6 Assessment by Product Type
• Figure 7 Assessment by Stage and Product Type
• Figure 8 Assessment by Route of Administration
• Figure 9 Assessment by Stage and Route of Administration
• Figure 10 Assessment by Molecule Type
• Figure 11 Assessment by Stage and Molecule Type
• Figure 12 Inactive Products

DelveInsight's, Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Understanding

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Overview

Fibroblast growth factors (FGF) and their tyrosine kinase receptors (FGFR) support cell proliferation, survival and migration during embryonic development, organogenesis and tissue maintenance and their deregulation is frequently observed in cancer development and progression. Consequently, increasing efforts are focusing on the development of strategies to target FGF/FGFR signaling for cancer therapy. Fibroblast growth factors (FGF) and their tyrosine kinase receptors (FGFR) regulate important cellular processes such as cell proliferation, survival and migration during embryonic development, organogenesis and tissue maintenance.

FGFR4 deletion does not lead to an embryonic lethal phenotype suggesting the possibility that its inhibition in cancer therapy might not cause grave adverse effects. The FGFR4 kinase domain differs sufficiently from those of FGFRs1-3 to permit development of highly specific inhibitors. The oncogenic impact of FGFR4, however, is not undisputed, as the FGFR4-mediated hormonal effects of several FGF ligands may also constitute a tissue-protective tumor suppressor activity especially in the liver.

"Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline landscape is provided which includes the disease overview and Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist treatment guidelines. The assessment part of the report embraces, in depth Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The therapies under development are focused on novel approaches to treat/improve Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist.

This segment of the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Emerging Drugs

• Pemigatinib: Incyte Corporation

Pemigatinib is an orally bioavailable, small molecule, and selective inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, 3 and 4. Pemigatinib is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.

• H3B-6527: H3 biomedicine

H3B-6527 is a selective, orally bioavailable, and covalent inhibitor of FGFR4 that has demonstrated tumor regression in several preclinical models of HCC. Receptor tyrosine kinases (RTKs) can be dysregulated in cancer cells and can frequently promote abnormally rapid tumor growth and development. Hepatocellular carcinoma (HCC) can be driven in this way by hyperactivation of the fibroblast growth factor receptor 4 (FGFR4). H3B-6527 is being tested specifically in patients with FGFR4-dysregulated advanced HCC.

Further product details are provided in the report……..

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Therapeutic Assessment

This segment of the report provides insights about the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist

There are approx. 15+ key companies which are developing the therapies Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist. The companies which have their Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drug candidates in the most advanced stage, i.e Phase III include, Helsinn.

• Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs.

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Insights

• Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs?
• How many Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Key Players

• H3 Biomedicine
• AiViva BioPharma
• Incyte Corporation
• Helsinn
• Astellas Pharma
• Taiho Oncology
• Eli Lilly and Company

Key Products

• H3B 6527
• Lenvatinib
• Pemigatinib
• Infigratinib
• ASP-5878
• Futibatinib
• LY 2874455

Table of Contents

Introduction

Executive Summary

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist: Overview

• What is Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist?
• Types of Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist
• Causes
• Epidemiology and Risk Factors
• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Infigratinib: Helsinn

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Pemigatinib: Incyte Corporation

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

H3B 6527: H3 Biomedicine

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Preclinical Stage Products

• Comparative Analysis

ASP5878: Astellas Pharma

• Product Description
• Research and Development
• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Key Companies

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Key Products

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- Unmet Needs

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- Market Drivers and Barriers

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist- Future Perspectives and Conclusion

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Analyst Views

Fibroblast Growth Factor Receptor 4 (FGFR4) Antagonist Key Companies

Appendix